Policy Update: DR.003.E Ocrevus (Ocrelizumab) and Ocrevus Zunovo (ocrelizumab-hyaluronidase ocsq)
September 3, 2026
Effective October 5, 2026, we will be implementing a revised drug policy: DR.003.E Ocrevus and Ocrevus Zunovo.
You can access this policy by visiting our policy bulletin library at policy bulletin library ( https://www.jeffersonhealthplans.com/providers/tools-and-resources/policy-bulletin-library).
As a reminder, our medical policy bulletins define medical necessity criteria and coverage positions on topics such as medical services, procedures, DME, therapies, etc., while our claim payment policy bulletins provide reimbursement rules and billing guidelines necessary to ensure timely and appropriate payment.